A few case reports suggest a reduced incidence of severe EAMs in RA patients treated with cyclophosphamide, methotrexate (MTX), and high-dose corticosteroid treatment; however, the effect of tumour necrosis factor (TNF)-inhibitors on EAMs is still under debate [1,7]. This evidence concerns the gene TNF and rheumatoid arthritis.